A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

As the US Supreme Court braces for legal challenges to President Donald Trump’s sweeping actions against Harvard University, the spotlight turns to judicial recusals—raising complex questions of bias, ...

Get the detailed quarterly/annual income statement for NOVARTIS AG N (NOT.DE). Find out the revenue, expenses and profit or loss over the last fiscal year.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 DevelopmentMelbourne, Australia and Oxford, UK– 2 June 2025, Aravax, a clinical-stage biotechnology ...

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...

In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Huntington’s disease affects an estimated 5 to 10 per 100,000 people in most Western countries, with variation by region and ...

Extended follow-up data from the CheckMate 274 trial have further solidified adjuvant nivolumab’s position as a standard of ...

Thornburg Investment Income Builder Fund paid ordinary dividends of $0.24 per I share during Q1’2025, flat versus Q1’24.

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...